CredenceResearch.com has Published New Research Report Title “Global Carcinoembryonic Antigen (CEA) Market, By Application (Ovarian Cancer, Colorectal Cancer, Pancreatic Cancer, Lung Cancer, Breast Cancer, Thyroid Cancer and Other Cancers) – Growth, Share, Opportunities & Competitive Analysis, 2016 -2023”The latest market report published by Credence Research, Inc. “Global Carcinoembryonic Antigen (CEA) Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2023,” the carcinoembryonic antigen (CEA) market was valued at USD 1,624.2 Mn in 2015, and is expected to reach USD 2,787.3 Mn by 2023, expanding at a CAGR of 6.4% from 2016 to 2023.
Market Insights
According to Quest Diagnostics, CEA is an oncofetal glycoprotein present in the gastrointestinal tract and body fluids of the embryo and fetus. This antigen is also present in certain adult gastrointestinal cells, including the mucosal cells of the colorectum, and small amounts are present in blood. Market experts suggest that key growth drivers assisting the growth of CEA market comprises high prevalence of cancer, mounting global geriatric population base, high demand for minimally invasive diagnostic procedures in cancer and increasing application of CEA for diagnosis at several stages of cancer. In addition, a few factors that assist the overall market growth are growing healthcare expenditure which is boosting the need for efficient diagnostic procedure for cancer and influencing the usage of combination biomarkers.
The global carcinoembryonic antigen (CEA) market is segmented on the basis of application type into ovarian cancer, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, thyroid cancer and other cancers. In base year 2015, colorectal cancer dominated the overall market in terms of revenue. The key factors responsible for growth of CEA market are increase in number of population consuming alcohol, sedentary lifestyle, and high intake of saturated fats in all age groups. Moreover, rising preference for CEA test in cancer diagnosis and management is expected to assist its market growth in the near future.
In base year 2015, North America was observed as the largest CEA market due to high public awareness related to early cancer diagnosis, rising preference for minimally invasive cancer diagnosis tests and sophisticated health care facilities for cancer management. Incessant technological developments followed by new discoveries of specific antigens and biomarkers are anticipated to boost the growth of CEA market testing. The key factors assisting the growth of CEA market comprises aging population, highly accessible technologically advanced healthcare facilities, successful governmental and non-governmental initiatives, and demand for precise diagnostic procedures.
Market Competition Assessment:
The carcinoembryonic antigen (CEA) market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Quest Diagnostics, F. Hoffman LA Roche, Abbott Laboratories, GenWay Biotech Inc., Correlogic Systems, Inc., and Others.
Browse the full report Carcinoembryonic Antigen (CEA) Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2023 report at http://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market
Key Market Movements:
- Rising prevalence of cancer is expected to drive the CEA tests market in the near future
- Increasing demand for minimally invasive diagnosis methods for cancer
- Growing healthcare expenditure in developing countries is assisting the growth of CEA tests
- The regulatory framework for approval process has always been the most critical restraining factor in the cancer diagnosis
- According to NICE, the specificity in detecting diseases is almost between 30-80% during CEA test for the diagnosis of early colorectal cancer. This test is much more useful in detecting prognosis other than early diagnostic phase, where the specificity is expected to be 65% of detecting diseases
Latest Report:
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
What we do
We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.
No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.
Web: Credence Research
Media Contact
Company Name: Credence Research
Contact Person: Chris Smith, Global Sales Manager
Email: Send Email
Phone: 1-800-361-8290
Address:105 N 1st ST #429
City: SAN JOSE
State: California
Country: United States
Website: http://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market
Source: www.abnewswire.com
